5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Diarrhea O
: O
Patients O
may O
experience O
severe O
diarrhea O
. O

If O
severe O
diarrhea O
occurs O
, O
suspend O
dosing O
and O
rehydrate O
the O
patient O
. O

( O
5.2 O
) O
5.1 O
Risk O
of O
Serious O
Dehydration O
in O
Pediatric O
Patients O
LINZESS O
is O
contraindicated O
in O
patients O
less O
than O
6 O
years O
of O
age O
. O

The O
safety O
and O
effectiveness O
of O
LINZESS O
in O
patients O
less O
than O
18 O
years O
of O
age O
have O
not O
been O
established O
. O

In O
neonatal O
mice O
( O
human O
age O
equivalent O
of O
approximately O
0 O
to O
28 O
days O
) O
, O
linaclotide O
increased B-NonOSE_AE
fluid I-NonOSE_AE
secretion I-NonOSE_AE
as O
a O
consequence O
of O
GC-C O
agonism O
resulting O
in O
mortality B-NonOSE_AE
within O
the O
first O
24 O
hours O
due O
to O
dehydration B-NonOSE_AE
. O

Due O
to O
increased O
intestinal O
expression O
of O
GC-C O
, O
patients O
less O
than O
6 O
years O
of O
age O
may O
be O
more O
likely O
than O
patients O
6 O
years O
of O
age O
and O
older O
to O
develop O
severe O
diarrhea B-NonOSE_AE
and O
its O
potentially O
serious O
consequences O
. O

Avoid O
use O
of O
LINZESS O
in O
pediatric O
patients O
6 O
years O
to O
less O
than O
18 O
years O
of O
age O
. O

Although O
there O
were O
no O
deaths B-NonOSE_AE
in O
older O
juvenile O
mice O
, O
given O
the O
deaths B-NonOSE_AE
in O
young O
juvenile O
mice O
and O
the O
lack O
of O
clinical O
safety O
and O
efficacy O
data O
in O
pediatric O
patients O
, O
avoid O
the O
use O
of O
LINZESS O
in O
pediatric O
patients O
6 O
years O
to O
less O
than O
18 O
years O
of O
age O
[ O
see O
Contraindications O
( O
4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

5.2 O
Diarrhea O
Diarrhea B-OSE_Labeled_AE
was O
the O
most O
common O
adverse O
reaction O
of O
LINZESS-treated O
patients O
in O
the O
pooled O
IBS-C O
and O
CIC O
double-blind O
placebo-controlled O
trials O
. O

The O
incidence O
of O
diarrhea B-OSE_Labeled_AE
was O
similar O
between O
the O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
and O
CIC B-Not_AE_Candidate
populations O
. O

Severe O
diarrhea B-OSE_Labeled_AE
was O
reported O
in O
2 O
% O
of O
145 O
mcg O
and O
290 O
mcg O
LINZESS-treated O
patients O
, O
and O
in O
< O
1 O
% O
of O
72 O
mcg O
LINZESS-treated O
CIC O
patients O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
post-marketing O
experience O
, O
severe O
diarrhea B-OSE_Labeled_AE
associated O
with O
dizziness B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
hypotension B-NonOSE_AE
and O
electrolyte B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
hypokalemia B-NonOSE_AE
and O
hyponatremia B-NonOSE_AE
) O
requiring O
hospitalization O
or O
intravenous O
fluid O
administration O
have O
been O
reported O
in O
patients O
treated O
with O
LINZESS O
. O

If O
severe O
diarrhea B-NonOSE_AE
occurs O
, O
suspend O
dosing O
and O
rehydrate O
the O
patient O
. O

